Hematology

The Division of Pediatric Hematology at Columbia University is committed to outstanding patient care, research, and education. Our mission is three-fold: 1) to provide personalized high quality, comprehensive care of children and adolescents with hematologic disorders; 2) to promote advances in biomedical research in the management of hematological conditions; and 3) to foster academic experience, education and training. Our Faculty provides expert inpatient and outpatient services from early diagnosis to continuing care and follow up of a wide spectrum of blood-related diseases.

Our newly established St. Giles Comprehensive Sickle Cell and Thalassemia Center provides comprehensive, family-centered care to pediatric patients with sickle cell disease and thalassemia. The Center is focused on guaranteeing consistent provision of the best evidence-based treatments, assuring early recognition of risks of preventable complications and providing dependable support for effective family and patient self-management. Our program provides a variety of services to the communities of Harlem, Northern Manhattan, and the tri-state area, including newborn screening in sickle cell disease, stroke prevention, chronic transfusion and iron-chelating therapy, pain management, community outreach, and patient education programs.

In addition to our clinical practice, the Division of Hematology has a range of on-going NIH-funded and investigator-initiated research initiatives, including research in iron deficiency and transfusional iron overload, iron metabolism, cerebral malaria, magnetic resonance imaging and measurement of heart and liver iron, pulmonary hypertension in sickle cell disease, hydroxyurea and oral chelation therapy in sickle cell anemia, vaso-occlusive pain management, and novel technologies in newborn screening. Our HRSA service project, in collaboration with General Pediatrics and community-based organizations, provides a coordinated care and follow up of newborns with sickle cell disease and other hemoglobinopathies. We are developing a patient database to monitor and evaluate clinical and therapeutic management, health resource utilization, and healthcare outcomes.